Idorsia (LTS:0RQE) Construction In Progress : CHF0.0 Mil (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Idorsia Construction In Progress?

Idorsia's annual construction in progress increased from Dec. 2020 (CHF20.8 Mil) to Dec. 2021 (CHF24.3 Mil) but then declined from Dec. 2021 (CHF24.3 Mil) to Dec. 2022 (CHF18.5 Mil).

Idorsia Construction In Progress Historical Data

The historical data trend for Idorsia's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia Construction In Progress Chart

Idorsia Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Construction In Progress

Get a 7-Day Free Trial

8.44

15.25

20.81

24.35

18.47

Idorsia Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Construction In Progress	Get a 7-Day Free Trial															-	18.47	-	-	-

Idorsia Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Idorsia (LTS:0RQE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (LTS:0RQE) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

IDRSF:USA IDIAz:UK IDIA:Switzerland

Address

Hegenheimermattweg 91, Allschwil, CHE, 4123

Website

https://www.idorsia.com

Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Idorsia (LTS:0RQE) Headlines

No Headlines